{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Chen PK"],"funding":["China Medical University Hospital"],"pagination":["6656121"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7963899"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["2021"],"pubmed_abstract":["Anti-drug antibody (ADAb) development is associated with secondary therapeutic failure in biologic-treated rheumatoid arthritis (RA) patients. With a treat-to-target goal, we aimed to identify biomarkers for predicting ADAb development and therapeutic response in adalimumab-treated patients. Three independent cohorts were enrolled. In Cohort-1, 24 plasma samples (6 ADAb-positive and 6 ADAb-negative patients at baseline and week 24 of adalimumab therapy, respectively) were assayed with immune-related microarray containing 1,636 correctly folded functional proteins. Next, we executed statistically powered autoantibody profiling analysis of 50 samples in Cohort-2 (24 ADAb-positive and 26 ADAb-negative patients). Subsequently, immunofluorescence assay was performed on 48 samples in Cohort-3 to"],"journal":["Journal of immunology research"],"pubmed_title":["Anti-TROVE2 Antibody Determined by Immune-Related Array May Serve as a Predictive Marker for Adalimumab Immunogenicity and Effectiveness in RA."],"pmcid":["PMC7963899"],"funding_grant_id":["DMR-109-207"],"pubmed_authors":["Lan JL","Anuar ND","Mamat RNR","Chen PK","Blackburn JM","Tan TM","Chen HH","Chang SH","Chung CM","Rutt NH","Chen DY","Chen YM"],"additional_accession":[]},"is_claimable":false,"name":"Anti-TROVE2 Antibody Determined by Immune-Related Array May Serve as a Predictive Marker for Adalimumab Immunogenicity and Effectiveness in RA.","description":"Anti-drug antibody (ADAb) development is associated with secondary therapeutic failure in biologic-treated rheumatoid arthritis (RA) patients. With a treat-to-target goal, we aimed to identify biomarkers for predicting ADAb development and therapeutic response in adalimumab-treated patients. Three independent cohorts were enrolled. In Cohort-1, 24 plasma samples (6 ADAb-positive and 6 ADAb-negative patients at baseline and week 24 of adalimumab therapy, respectively) were assayed with immune-related microarray containing 1,636 correctly folded functional proteins. Next, we executed statistically powered autoantibody profiling analysis of 50 samples in Cohort-2 (24 ADAb-positive and 26 ADAb-negative patients). Subsequently, immunofluorescence assay was performed on 48 samples in Cohort-3 to","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021","modification":"2025-04-21T23:34:17.612Z","creation":"2025-04-05T19:14:44.617Z"},"accession":"S-EPMC7963899","cross_references":{"pubmed":["33763493"],"doi":["10.1155/2021/6656121"]}}